Edition:
United States

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

5,767JPY
26 May 2017
Change (% chg)

¥-33 (-0.57%)
Prev Close
¥5,800
Open
¥5,802
Day's High
¥5,828
Day's Low
¥5,757
Volume
1,823,900
Avg. Vol
2,109,292
52-wk High
¥5,856
52-wk Low
¥4,098

Select another date:

Tue, May 16 2017

BRIEF-Teva Takeda Pharma to up overseas production of generic medication to cut costs - Nikkei

* Teva takeda pharma to increase overseas production of generic medication to cut costs per year as drug prices continue to decline - Nikkei Source text (http://s.nikkei.com/2qOMEN4) Further company coverage:

BRIEF-Takeda Pharmaceutical announces further details of transformational pharmaceutical sciences partnership with Bushu

* Says it has entered into an agreement for an absorption-type company split with its wholly-owned subsidiary, SPERA PHARMA, Inc. on May 15

BRIEF-Takeda Pharmaceutical to transfer partial pharmaceutical research businesses to succeeding company

* Says it will transfer a part of Takeda's pharmaceutical research businesses to the succeeding company, effective July 1

BRIEF-Biologics Inc says selected by Takeda to be specialty pharmacy provider

* Selected by Takeda Pharmaceutical through unit to be specialty pharmacy provider as part of distribution network for Alunbrig (Brigatinib) Source text for Eikon: Further company coverage:

U.S. FDA approves Takeda's lung cancer drug as second-line treatment

Japan's Takeda Pharmaceutical Co Ltd said on Friday that the U.S. Food and Drug Administration approved its lung cancer drug, almost three months after the company acquired the drug's developer, Ariad Pharmaceuticals Inc.

U.S. FDA approves Takeda's lung cancer drug as 2nd-line treatment

April 28 Japan's Takeda Pharmaceutical Co Ltd said on Friday that the U.S. Food and Drug Administration approved its lung cancer drug, almost three months after the company acquired the drug's developer, Ariad Pharmaceuticals Inc.

BRIEF-Takeda announces FDA accelerated approval of ALUNBRIG

* Takeda announces FDA accelerated approval of ALUNBRIG(brigatinib)

BRIEF-Takeda, Harrington Discovery Institute announce collaboration

* Takeda and Harrington Discovery Institute at University Hospitals announce a collaboration to advance the development of Rare Disease Therapeutics Source text for Eikon: Further company coverage:

J&J, Novartis and Takeda in talks for Brazil's Hypermarcas, sources say

SAO PAULO, April 24 Johnson & Johnson, Novartis AG and Takeda Pharmaceutical Co Ltd are in talks with the controlling bloc of Brazilian drugmaker Hypermarcas SA for a buyout, two people with knowledge of the matter said on Monday.

Takeda's largest study brings dengue vaccine step closer

Japan's Takeda Pharmaceutical said on Wednesday it had completed enrolment for a 20,000-subject dengue vaccine trial, the largest clinical study in its history, signalling the global ambitions of its vaccine business.

Select another date:

More From Around the Web